Nektar Therapeutics Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Nektar Therapeutics (NKTR) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $33.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-13
- Nektar Therapeutics valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $33.30M, a 623.91% increase from fiscal 2024.
- Nektar Therapeutics valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $4.60M, a 87.99% decline from fiscal 2023.
- Nektar Therapeutics valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $38.30M, a 25.57% increase from fiscal 2022.
- Nektar Therapeutics valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $30.50M, a 73.62% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $33.30M 10-K · filed 2026-03-13 | |
| 2024-12-31 | $4.60M 10-K · filed 2026-03-13 | |
| 2023-12-31 | $38.30M 10-K · filed 2025-03-14 | |
| 2022-12-31 | $30.50M 10-K · filed 2024-03-05 | |
| 2021-12-31 | $115.60M 10-K · filed 2023-02-28 | |
| 2020-12-31 | -$95.00M 10-K · filed 2022-03-01 | |
| 2019-12-31 | -$114.60M 10-K · filed 2021-02-26 | $114.60M 10-K · filed 2020-02-28 |
| 2018-12-31 | -$35.70M 10-K · filed 2020-02-28 | |
| 2017-12-31 | -$169.30M 10-K · filed 2020-02-28 | |
| 2016-12-31 | $52.50M 10-K · filed 2019-03-01 | |
| 2015-12-31 | $17.30M 10-K · filed 2018-03-01 | |
| 2014-12-31 | $9.70M 10-K · filed 2016-02-29 | |
| 2013-12-31 | $51.80M 10-K · filed 2015-02-26 | |
| 2012-12-31 | $43.60M 10-K · filed 2014-02-27 | |
| 2011-12-31 | $52.90M 10-K · filed 2013-03-01 | |
| 2010-12-31 | $8.30M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |